Oukat H Tablet is a combination antihypertensive medication containing Hydrochlorothiazide 12.5 mg and Olmesartan Medoxomil 20 mg. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, thereby reducing blood volume and lowering blood pressure. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation and decreased aldosterone secretion, which further contributes to blood pressure reduction. The combination of these two agents provides complementary mechanisms of action, resulting in enhanced antihypertensive efficacy compared to monotherapy. Oukat H Tablet is indicated for the treatment of essential hypertension to achieve better blood pressure control and reduce the risk of cardiovascular morbidity and mortality. It is typically prescribed when monotherapy is insufficient or when combination therapy is deemed appropriate. Patients should be monitored for electrolyte imbalances, renal function, and blood pressure response during treatment. Common adverse effects may include dizziness, hypotension, hyperkalemia, and electrolyte disturbances. Oukat H Tablet should be used under medical supervision with appropriate dosage adjustments based on clinical response and tolerability.